List of Topics | WCPD 2027

01 Topics

Every session topic at WCPD 2027.

A complete, searchable index of session topics across 35 scientific sessions. Use this page to plan your attendance or to find the right call for your abstract submission.

01 Track

Drug Discovery & Design

Target ID, fragment-based, AI/ML-driven design.

Track details

Generative chemistry and AlphaFold 3-guided structure-based design
Targeted protein degradation: PROTACs, molecular glues, ARV-471
KRAS, p53, and previously undruggable target classes
DNA-encoded libraries and fragment-based lead discovery
Oral peptides, macrocycles, and beyond-rule-of-five chemistry
Phenotypic screening and AI-driven phenomics (Recursion, Insitro)
Covalent drug design and chemoproteomics target ID

02 Track

Clinical Pharmacology

PK/PD, dose-finding, adaptive trials, special populations.

Track details

Project Optimus: oncology dose optimization beyond MTD
Model-informed drug development and PBPK in special populations
Decentralized clinical trials, wearables, and remote dosing
Adaptive, platform, and master protocol trial designs
First-in-human dosing for bispecifics, CAR-T, and radioligands
Pediatric, pregnancy, and lactation pharmacology (PREA, BPCA)
Drug-drug interactions: transporter and CYP-mediated risk

03 Track

Pharmacogenomics & Precision Medicine

CYP variants, biomarker-guided dosing, companion diagnostics.

Track details

CPIC-actionable pairs: DPYD, TPMT, CYP2C19, CYP2D6, HLA-B
Pre-emptive panel testing and EHR clinical decision support
Companion diagnostics: KRAS, EGFR, BRCA, MSI/dMMR, NTRK
Ancestry diversity in pharmacogenomic reference data
Tumor-agnostic approvals and basket trial pharmacology
Polygenic scores for drug response and adverse events
Pharmacogenomics in psychiatry: SSRI, antipsychotic dosing

04 Track

Drug Delivery Systems

Nanoparticles, microneedles, oral peptides, gene delivery.

Track details

LNP engineering: extrahepatic tropism and ionizable lipids
GalNAc-siRNA platforms: inclisiran, vutrisiran, zilebesiran
Oral peptide delivery: SNAC, permeation enhancers, orforglipron
AAV capsid engineering and re-dosing strategies
In-vivo CRISPR delivery and Casgevy ex-vivo manufacturing
Microneedle patches and long-acting injectable depots
Blood-brain barrier crossing: transferrin-receptor shuttles

05 Track

Toxicology & Safety Pharmacology

Organ-on-chip, predictive toxicology, immune-related toxicities.

Track details

FDA Modernization Act 2.0 and microphysiological systems
Organ-on-chip: liver, cardiac, kidney, gut, BBB platforms
CAR-T and bispecific toxicity: CRS, ICANS, on-target off-tumor
ADC class toxicities: ocular, ILD, neutropenia management
In silico DILI and hERG/proarrhythmia prediction
Genotoxicity and nitrosamine impurity risk assessment
Immune-related adverse events from checkpoint inhibitors

06 Track

Regulatory Science & Policy

FDA, EMA, ICH guidelines, accelerated approval.

Track details

IRA Medicare price negotiation: 2026/2027/2028 selected drugs
Accelerated approval reform and confirmatory trial mandates
Cell and gene therapy CMC and pre-approval inspections
FDA, EMA, PMDA, NMPA harmonization and ICH E6(R3)
AI/ML-enabled software as a medical device (SaMD)
PBM reform, 340B, and biosimilar interchangeability
Real-world evidence in regulatory submissions (21st Century Cures)

07 Track

Pharmacovigilance

Real-world evidence, signal detection, patient registries.

Track details

FDA Sentinel and active surveillance for novel modalities
GLP-1 receptor agonist safety: GI, ocular, suicidality signals
Compounded GLP-1 quality and adverse event reporting
Gene therapy long-term registries and delayed toxicities
NLP and ML for ICSR triage and social-media signal detection
REMS modernization and risk minimization measurement
Pregnancy and lactation registries; teratovigilance

08 Track

Biopharmaceuticals

Monoclonal antibodies, ADCs, bispecifics, gene/cell therapies.

Track details

ADC platform expansion: linker-payload chemistry, dual payloads
T-cell engagers: teclistamab, talquetamab, tarlatamab, blinatumomab
In-vivo CAR-T via LNP-mRNA and engineered AAV
Anti-amyloid mAbs: lecanemab, donanemab, ARIA management
Biosimilar interchangeability and Humira/Stelara market dynamics
AAV gene therapy: Hemgenix, Elevidys, Roctavian, Zolgensma
Allogeneic and iPSC-derived off-the-shelf cell therapies

09 Track

Pharmaceutical Manufacturing

Continuous manufacturing, QbD, biosimilars, supply-chain.

Track details

Continuous manufacturing and ICH Q13 implementation
mRNA, LNP, and viral vector manufacturing scale-up
Nitrosamine impurity control and root-cause investigation
GLP-1 supply chain, compounding, and FDA shortage list
Generics quality: GDUFA III, FDA foreign inspections
Distributed and point-of-care cell therapy manufacturing
PAT, real-time release, and Quality-by-Design (ICH Q8-Q12)

Have research aligned to one of these topics?

Submit your abstract by December 20, 2026. Oral and poster presentations are welcome across all nine tracks.

Submit Abstract